- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| 19.02. | Basilea Pharmaceutica - Another year, another market beat | 436 | Basilea recorded another strong year in FY24, its third successive year of cash flow positivity and its strongest operating performance to date. Lead drug Cresemba continued to dominate performance... ► Artikel lesen | ||
| 18.02. | PZ Cussons - Less is more | 288 | PZ Cussons (PZC) is in transition. Both St Tropez (largely a US business) and Africa (mainly Nigeria) are potentially worth more to others than they are to PZC. Their disposal will reduce earnings volatility... ► Artikel lesen | ||
| 18.02. | IRLAB Therapeutics - Financing improves operational flexibility | 203 | IRLAB Therapeutics has renegotiated its loan terms with Fenja Capital, allowing it to extend the duration of its SEK55m loan from 22 May 2025, potentially to 30 June 2026. The loan value may also be... ► Artikel lesen | ||
| 18.02. | Molten Ventures - Investor day: Five strategic priorities outlined | 162 | During Molten Ventures' recent investor day, Ben Wilkinson (who was appointed CEO in October 2024 after serving as Molten's CFO for eight years) outlined the strategic priorities for the business. These... ► Artikel lesen | ||
| 18.02. | The Diverse Income Trust - An exciting time for UK investors - enjoy the ride | 147 | The Diverse Income Trust's (DIVI's) portfolio is broadly diversified by sector and market cap, offering the potential for good upside in rising markets, and unlike the UK market, has consistently grown... ► Artikel lesen | ||
| 18.02. | Dentsu Group - Mid-term management plan in place | 206 | Dentsu has published its FY24 results, which show a strong Q424 in its Japanese business, ensuring that the group effectively met November's net revenue guidance despite continuing weakness in international... ► Artikel lesen | ||
| 18.02. | Lowland Investment Company - Dividends and buybacks rewarding patience | 243 | Lowland Investment Company's (LWI's) unconstrained, multi-cap investment policy differentiates it from most peers in the AIC UK Equity Income sector, offering investors broad market exposure outside... ► Artikel lesen | ||
| 18.02. | Topps Tiles - Nearing resolution of CMA review | 256 | The announcement that the Competition and Markets Authority (CMA) has found Topps Tiles' (TPT's) acquisition of CTD Tiles generates no competition concerns in the majority of the areas reviewed should... ► Artikel lesen | ||
| 18.02. | British American Tobacco - Moving to a smokeless world | 944 | British American Tobacco's (BAT's) strategy is to become a predominantly smokeless business, generating more than 50% of revenue (FY24: 17.5%) from smokeless products by FY35. The industry backdrop... ► Artikel lesen | ||
| 18.02. | IRLAB Therapeutics (STO: IRLAB-A) announces loan term extension and new shareholder loan | 252 | IRLAB has renegotiated its loan terms with FENJA Capital, allowing it to extend duration of the SEK55m loan from May 2025 to 31 December 2025 and potentially to 30 June 2026 (for an additional fee of... ► Artikel lesen | ||
| 17.02. | Theon International - Strong FY24 results; FY25 guidance confirmed | 325 | Theon has reported a strong set of maiden results as a listed company, along with good growth in order backlog, supporting positive guidance for FY25. Equally important are the operational milestones... ► Artikel lesen | ||
| 17.02. | GSK's (LSE: GSK) five-in-one vaccine approved by the FDA | 396 | GSK's five-in-one meningococcal vaccine, Penmenvy, has been approved by the US FDA for the treatment of meningitis, an indication that, in extreme cases, can lead to deadly brain swelling. More specifically... ► Artikel lesen | ||
| 17.02. | Topps Tiles (LSE:TPT) - CTD Tiles acquisition generated no competition concerns in majority of areas reviewed | 231 | Topps Tiles has announced the Competition and Markets Authority (CMA) found the proposed acquisition generated no competition concerns in the majority of areas reviewed. The CMA has identified possible... ► Artikel lesen | ||
| 14.02. | Knowit - Positive signs amid strong headwinds | 307 | Knowit reported signs of recovery at the end of a challenging 2024 that saw headcount reduced by 10%. Management has not only downsized the business but also taken steps to improve efficiency. This... ► Artikel lesen | ||
| 14.02. | Oryzon (BME: ORY) publishes REIMAGINE results in prestigious journal | 284 | Oryzon Genomics has announced the publication of the final Phase IIa REIMAGINE results in the journal Psychiatry and Clinical Neurosciences. The REIMAGINE trial evaluated the safety and efficacy of... ► Artikel lesen | ||
| 14.02. | Pinewood Technologies (LSE: PINE) signs significant new contract | 290 | Pinewood Technologies has signed a five-year contract with Global Auto Holdings (GAH) to implement the Pinewood Automotive Intelligence platform into all of its owned dealerships in the UK, North America... ► Artikel lesen | ||
| 13.02. | Actinogen Medical - XanaMIA Phase IIb/III study marches on | 240 | Actinogen Medical continues to make progress with its 36-week XanaMIA Phase IIb/III study assessing Xanamem in patients with biomarker-positive mild-to-moderate Alzheimer's disease (AD). The company... ► Artikel lesen | ||
| 13.02. | Mendus - Focus firmly on pivotal-stage readiness in 2025 | 238 | Mendus's FY24 results and subsequent management presentation highlighted its focus on advancing lead asset, vididencel, to pivotal-stage readiness. Backed by robust long-term monotherapy data from ADVANCE... ► Artikel lesen | ||
| 13.02. | Creo Medical - Consumables business divestment concludes | 193 | Creo Medical has completed the sale of the majority (51%) stake in its European consumable business to Chinese medical device manufacturer Micro-Tech for net proceeds of c €30m (c £25m). The deal valued... ► Artikel lesen | ||
| 13.02. | Cereno Scientific - CS014 achieves another Phase I milestone | 172 | Cereno Scientific's second pipeline asset, CS014, continues to make steady progress through the clinic, with the company successfully completing the single ascending dose (SAD) part of the Phase I study... ► Artikel lesen | ||
| 13.02. | British American Tobacco (LSE: BATS) - FY24 results in line | 596 | British American Tobacco (BAT) navigated a year of transformation in 2024, with its pivot towards a smokeless future gaining momentum. The company added 3.6 million new adult users of its smokeless... ► Artikel lesen | ||
| 13.02. | RELX (LSE: REL) - Good momentum into FY25 | 272 | RELX has turned in a very good performance for 2024, with underlying revenue growth of 7% and a step-up in adjusted operating margin from 33.1% to 33.9%. Encouragingly, there was progress in margin... ► Artikel lesen | ||
| 13.02. | Immix Biopharma - NXC-201 receives FDA RMAT designation | 179 | Immix Biopharma has been granted a Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food and Drug Administration (FDA) for the company's novel sterically optimized CAR-T treatment... ► Artikel lesen | ||
| 12.02. | Claranova - Stable performance in H125 | 306 | Claranova's underlying revenue was essentially flat year-on-year in H125. While underlying revenue grew 3% for Avanquest, PlanetArt felt the effects of a shorter holiday season in the US, with underlying... ► Artikel lesen | ||
| 12.02. | S&U - A tale of two businesses | 240 | S&U published an update on trading to 31 January (end-FY25) and will release its annual results on 15 April. Group performance continues to be characterised by strong growth in the property lending... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
